Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.88 USD | -2.89% | -9.80% | -21.92% |
Jun. 12 | Transcript : Affimed N.V., Q1 2024 Earnings Call, Jun 12, 2024 | |
Jun. 12 | Affimed N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Chart calendar Affimed N.V.
Upcoming events on Affimed N.V.
Past events on Affimed N.V.
2024-06-26 03:00 am | Annual General Meeting |
2024-06-12 | EHA Hybrid Congress |
2024-06-12 08:30 am | Q1 2024 Earnings Call |
2024-06-12 06:30 am | Q1 2024 Earnings Release |
2024-06-01 07:00 pm | American Society of Clinical Oncology Meeting |
2024-06-01 10:00 am | American Society of Clinical Oncology Meeting - Abstract No 2522 |
2024-03-28 08:30 am | Q4 2023 Earnings Call |
2024-03-28 06:30 am | Q4 2023 Earnings Release |
2023-12-11 09:00 pm | American Society of Hematology Meeting - AFM13 in Combination with Allogeneic Natural Killer Cells |
2023-12-11 04:30 pm | American Society of Hematology Meeting |
2023-12-11 02:45 pm | American Society of Hematology Meeting - Innate Cell Engager |
2023-11-15 08:30 am | Jefferies London Healthcare Conference |
2023-11-14 08:30 am | Q3 2023 Earnings Call |
2023-11-14 06:30 am | Q3 2023 Earnings Release |
2023-11-13 | PEGS Europe Conference |
2023-11-07 | Truist Securities Healthcare Conference |
2023-11-03 08:10 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number: 329 |
2023-11-03 03:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number: 329 |
2023-09-28 01:15 pm | Cantor Global Healthcare Conference |
2023-09-25 | NK Society for Natural Immunity Meeting |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million EUR | Released Forecast Spread | 21,4 19,8 7.93% | 28,4 32,0 -11.48% | 40,4 38,3 5.47% | 41,4 37,6 9.95% | 8,28 9,48 -12.74% | 4,75 |
EBITDA Million EUR | Released Forecast Spread | 0,00 0,00 - | -33,6 -32,0 -5.01% | -62,7 -60,7 -3.37% | -85,2 -80,0 -6.53% | 0,00 0,00 - | 0,00 |
EBIT Million EUR | Released Forecast Spread | -32,4 -35,1 7.83% | -34,7 -24,9 -39.48% | -64,0 -61,4 -4.22% | -88,1 -87,7 -0.53% | -107 -111 3.93% | -67,5 |
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -32,4 -33,5 3.45% | -41,4 -28,0 -47.78% | -57,5 -55,9 -2.92% | -86,0 -83,6 -2.85% | -106 -109 3.02% | -66,0 |
Net income Million EUR | Released Forecast Spread | -32,4 -33,1 2.35% | -41,4 -27,1 -52.48% | -57,5 -55,6 -3.54% | -86,0 -82,8 -3.9% | -106 -109 2.69% | -68,5 |
EPS EUR | Released Forecast Spread | -5,00 -5,06 1.19% | -5,00 -3,27 -53.14% | -4,80 -4,69 -2.35% | -6,00 -5,78 -3.87% | -7,09 -7,28 2.65% | -3,94 |
Announcement Date | 28/04/20 | 15/04/21 | 31/03/22 | 23/03/23 | 28/03/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million EUR | Released Forecast Spread | 8,01 9,29 -13.79% | 7,30 7,63 -4.27% | 14,9 7,40 101.23% | 11,2 6,52 71.14% | 4,51 5,70 -20.89% | 1,39 4,32 -67.81% | 1,96 1,89 3.98% | 0,41 1,55 -73.39% | 0,16 0,96 -83.9% | 1,15 | 1,50 | 1,53 | 0,50 | 0,50 |
EBITDA Million EUR | Released Forecast Spread | -21,3 -22,8 6.53% | |||||||||||||
EBIT Million EUR | Released Forecast Spread | -17,1 -25,3 32.29% | -21,7 -23,3 6.92% | -19,2 -27,1 29.2% | -30,1 -30,3 0.69% | -31,5 -28,8 -9.33% | -29,4 -28,4 -3.74% | -24,9 -28,2 11.75% | -20,8 -24,8 16.06% | -19,5 -24,6 20.44% | -17,0 | -15,9 | -15,2 | -18,5 | -21,5 |
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -16,7 -23,0 27.53% | -19,4 -24,0 19.28% | -16,5 -28,0 41.14% | -33,4 -30,7 -8.83% | -32,0 -28,2 -13.39% | -29,4 -26,6 -10.63% | -24,4 -27,4 11.25% | -20,2 -24,1 16.21% | -19,2 -23,1 17.05% | -16,4 | -15,6 | -14,7 | -18,0 | -18,0 |
Net income Million EUR | Released Forecast Spread | -16,7 -21,5 22.32% | -19,4 -23,9 18.63% | -16,5 -26,9 38.66% | -33,4 -29,8 -12.09% | -32,0 -28,7 -11.56% | -29,4 -27,9 -5.42% | -24,4 -27,5 11.54% | -20,2 -23,6 14.44% | -19,2 -23,9 19.75% | -17,1 | -16,6 | -15,5 | -18,5 | -21,0 |
EPS EUR | Released Forecast Spread | -1,40 -1,81 22.6% | -1,30 -1,70 23.42% | -1,10 -1,79 38.5% | -2,20 -1,94 -13.26% | -2,10 -1,92 -9.46% | -2,00 -1,90 -5.4% | -1,60 -1,84 13.1% | -6,52 -1,57 -316.61% | -1,27 -1,55 18.09% | -1,03 | -0,94 | -0,76 | -0,60 | -0,65 |
Announcement Date | 01/06/22 | 11/08/22 | 15/11/22 | 23/03/23 | 23/05/23 | 10/08/23 | 14/11/23 | 28/03/24 | 12/06/24 | - | - | - | - | - |
Past sector events for Affimed N.V.
2024-06-05 03:51 am | PHARMAESSENTIA CORPORATION: May 2024 Sales and Revenue Release |
2024-05-17 07:00 am | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
2024-05-16 07:46 am | BIOCON LIMITED: Q4 2024 Earnings Release |
2024-05-16 01:00 am | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
2024-05-15 | LIGACHEM BIOSCIENCES INC.: Q1 2024 Earnings Release |
2024-05-15 08:05 am | THIRD HARMONIC BIO, INC.: Q1 2024 Earnings Release |
2024-05-15 07:00 am | CABALETTA BIO, INC.: Q1 2024 Earnings Release |
2024-05-14 | TAIMED BIOLOGICS INC.: Q1 2024 Earnings Release |
2024-05-14 04:05 pm | ENLIVEN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-14 04:00 pm | ARCUTIS BIOTHERAPEUTICS, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- AFMD Stock
- Calendar Affimed N.V.